Literature DB >> 26038135

[Preretinal hemorrhage and prognosis following vitrectomy and silicone oil tamponade for severe proliferative diabetic retinopathy].

Jiu-ke Li1, Xiao-hong Jin1, Wei Fang1, Li-guo Feng1, Jing Zhai1, Yu-min Li1.   

Abstract

OBJECTIVE: To examine the prognosis of preretinal hemorrhage following vitrectomy and silicone oil tamponade for severe proliferative diabetic retinopathy.
METHODS: Clinical data of 76 cases of proliferative diabetic retinopathy treated with vitrectomy and silicone oil infusion tamponade in Sir Run Run Shaw Hospital from October 2006 to September 2013 were retrospectively reviewed. Intraoperative bleeding,postoperative preretinal bleeding,blood reabsorption time, and preretinal fibrosis were assessed.
RESULTS: All preretinal hemorrhage developed within 1 week after surgery, blood was distributed in thin and scattered patterns (32 cases), thick and localized patterns (25 cases) or thick and scattered patterns (19 cases). The preretinal hemorrhage was ceased in 1 day after operation in 35 cases, in 2 days after operation in 18 cases, in two weeks after operation in 23 case. Recurrent hemorrhage occurred within 1 week after operation in 15 cases. Thin blood was largely reabsorbed in about two weeks, and thick blood was largely reabsorbed in about five weeks. Fibrosis tissue was resulted in 15 cases(34.1%) with thick blood.
CONCLUSION: Most of preretinal hemorrhage occurs within 1 week after surgery and is reabsorpted with 5 weeks in patients with proliferative diabetic retinopathy undergoing vitrectomy and silicone oil tamponade. The major complication of preretinal bleeding is the formation of preretinal fibrosis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26038135     DOI: 10.3785/j.issn.1008-9292.2015.03.008

Source DB:  PubMed          Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban        ISSN: 1008-9292


  1 in total

1.  Downregulation of angiogenic factors in aqueous humor associated with less intraoperative bleeding in PDR patients with NVG receiving conbercept: a randomized controlled trial.

Authors:  Qing Xu; Chaoju Gong; Lei Qiao; Ruifang Feng; Haiyang Liu; Yalu Liu; Liu Yang; Wei Fan; Lina Guan; Jie Li; Yipeng Zhang; Suyan Li
Journal:  BMC Ophthalmol       Date:  2022-05-18       Impact factor: 2.086

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.